查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1750679

全球肝癌診斷市場：市場規模、市場佔有率、趨勢分析（按測試類型、最終用途和地區）、細分市場預測（2025-2030 年）

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肝癌診斷市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球肝癌診斷市場規模預計到2030年將達到146.7632億美元，2025年至2030年的複合年成長率為6.67%。

肝癌盛行率的不斷上升、診斷技術的進步以及對篩檢對治療和存活率重要性的認知正在推動肝癌診斷市場的成長。

根據美國癌症協會的統計，預計 2022 年將診斷出約 41,260 例新的肝癌病例。此外，根據 Globocan 2020 年的報告，全球約有 830,180 人將死於肝癌。世界衛生組織也估計，慢性肝炎病毒感染在人群中廣泛存在，約有 5800 萬人感染C型肝炎病毒(HCV)。 HCV 和B型肝炎病毒 (HBV) 是肝癌最常見的危險因子。此外，感染或接觸肝硬化和吸菸等其他危險因子將激增對篩檢解決方案的需求，以便早期治療和診斷肝癌，提高存活率。因此，預測期內對診斷產品的需求將上升，推動市場成長。

COVID-19 疫情擾亂了肝癌患者的治療，導致死亡率上升。篩檢和治療的延誤和中斷也對肝癌患者產生了影響。例如，在 2021 年 6 月的一篇論文中，來自歐洲國家的研究人員評估了疫情對肝癌患者日常醫療照護的影響，並得出結論，這些調整顯著改變了治療結果。然而，在 COVID-19 疫情期間，技術的進步和對免疫系統的更深入理解，促成了許多新的醫療診斷方法的推出。此外，疫情也提高了人們對健康的重視，促使人們定期進行健康檢查，以便及早診斷和治療。

診斷技術的進步得益於世界各地許多公共和私人機構的認知提升和支持舉措。這將促進各種癌症的篩檢和診斷，並有望推動診斷解決方案的成長。例如，2022年9月，美國診斷公司Delfi Diagnostics, Inc.宣布，已被選為歐洲一項大規模篩檢試驗的液態切片合作夥伴。

為了滿足對肝癌早期檢測創新解決方案日益成長的需求，多家公司正在推出新產品。例如，2020年3月，羅氏公司榮獲「突破性設備」獎。羅氏公司憑藉其全新的Elecsys GALAD評分系統獲得了美國食品藥物管理局（FDA）頒發的「突破性設備稱號」。此評分系統透過向臨床醫生提供及時準確的資訊，支持肝細胞癌（HCC）的診斷。各大公司也在尋求聯合研究、合約和合作夥伴關係，以開發新產品。此類產品開發和市場拓展將加劇市場競爭，並促進肝癌診斷市場的成長。

肝癌診斷市場：分析概述

  • 從檢測類型來看，由於對精準且經濟高效的疾病分期的需求不斷成長，實驗室檢測在2024年佔據了最大佔有率。此外，用於監測治療方案療效的實驗室檢測應用也推動了這一成長。
  • 根據最終用途，醫院和診斷實驗室部門在 2024 年佔據了市場主導地位。人們傾向於將這些環境作為在醫療專業人員的幫助下進行診斷和治療的初級保健中心，這推動了這一部門的成長。
  • 由於人口中風險因素的普遍存在，北美將在2024年佔據最高佔有率。這是因為該地區對疾病篩檢的認知不斷提高，以及先進技術的採用推動了這一成長。
  • 預測期內，亞太地區將呈現最快的複合年成長率。此外，新興經濟體將推動該地區新興國家對診斷檢測的採用。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章肝癌診斷市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 肝癌診斷市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章肝癌診斷市場：按測試類型估計和趨勢分析

  • 細分儀表板
  • 肝癌診斷市場：依檢測類型進行波動分析
  • 肝癌診斷市場規模及依檢測類型趨勢分析（2018-2030）
    • 全球臨床檢測市場（2018-2030）
    • 影像學診斷
    • 內視鏡檢查
    • 切片檢查

第5章肝癌診斷市場：依最終用途的估計和趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球肝癌診斷市場：依最終用途分類的展望
  • 市場規模預測及趨勢分析（2018-2030年）
  • 醫院和診斷實驗室
    • 全球醫院和診斷實驗室市場（2018-2030）
  • 學術研究所
    • 全球學術研究機構市場（2018-2030）
  • 製藥/CRO實驗室
    • 全球製藥和 CRO 實驗室市場（2018-2030 年）

第6章肝癌診斷市場：按地區估計和趨勢分析

  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 最新趨勢和影響分析：按主要製造商
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Qiagen NV
    • Siemens Healthineers
    • Becton, Dickinson &Company
    • Illumina, Inc.
    • Epigenomics AG
    • Koninklijke Philips NV
    • Fujifilm Medical Systems USA, Inc.
Product Code: GVR-3-68038-012-5

Liver Cancer Diagnostics Market Growth & Trends:

The global liver cancer diagnostics market size is estimated to reach USD 14,676.32 million by 2030, registering a CAGR of 6.67% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

The COVID-19 pandemic disrupted liver cancer patient care and resulted in higher mortality rates. The delayed or interrupted screening & procedures impacted the patients with the disease. For example, in a June 2021 article, researchers from European countries assessed the pandemic's impact on routine care of liver cancer patients and concluded that the modifications significantly altered the outcomes. However, with advancements in technology and a better understanding of the immune system during COVID-19, many new healthcare diagnostic products have been launched. Moreover, the pandemic boosted the importance of health and pushed the population toward regular health screening for early diagnosis & treatment.

The technological advancement in diagnosis has resulted from increased awareness and supportive initiatives by many public-private organizations worldwide. This will result in a conducive environment to increase the screening as well as diagnosis of various cancers and is expected to propel the growth of diagnostics solutions. For example, in September 2022, Delfi Diagnostics, Inc., a U.S.-based diagnostics company, announced that it has been selected as the liquid biopsy partner in a large-scale screening trial in Europe.

To cater to the increased demand for innovative solutions for the early detection of liver cancer, multiple companies are launching new products. For instance, in March 2020, F. Hoffmann-La Roche Ltd. Roche received the 'Breakthrough Device Designation' from the US FDA for its new Elecsys GALAD score. The score supports clinicians in the diagnosis of hepatocellular carcinoma (HCC) by providing them with timely and accurate information. Key companies are also undergoing collaborations, agreements, and partnerships for new product developments. Such product developments & launches will intensify the market competition and fuel the market growth for liver cancer diagnostics.

Liver Cancer Diagnostics Market Report Highlights:

  • On the basis of test type, laboratory tests held the largest share in 2024, owing to the increased demand for accurate & cost-effective diagnosis of disease stages. In addition, the application of laboratory tests for monitoring response to treatment plans also propels the growth
  • Based on end-use, the hospitals and diagnostic laboratories segment dominated the market in 2024. The preference for these settings as primary care centers for the diagnosis and treatment with the help of medical professionals boosts the segment's growth
  • North America accounted for the highest share in 2024, due to the prevalence of risk factors in the population. This has resulted from the increased awareness about disease screening and the growing adoption of advanced technologies in this region, driving the growth
  • Asia Pacific will exhibit the fastest CAGR during the forecast period, owing to the prevalence of diseases and the presence of a large geriatric population in the region. In addition, the developing economies will boost the adoption of diagnostic tests in the region's emerging countries.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Incidence of Liver Cancer
      • 3.2.1.2. Technological Advancements
      • 3.2.1.3. Extensive R&D For Developing Novel Testing Solutions
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic imaging
  • 3.3. Liver Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Liver Cancer Diagnostics Market: Test type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Cancer Diagnostics Market: Product Movement Analysis
  • 4.3. Liver Cancer Diagnostics Market Size & Trend Analysis, by test type, 2018 to 2030 (USD Million)
    • 4.3.1. Global Laboratory Tests Market, 2018 - 2030 (USD Million)
      • 4.3.1.1. Biomarkers
        • 4.3.1.1.1. Global biomarkers market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.1. Oncofetal and Glycoprotein Antigens
            • 4.3.1.1.1.1.1. Global oncofetal and glycoprotein antigens market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.2. Enzymes and Isoenzymes
            • 4.3.1.1.1.2.1. Global enzymes and isoenzymes market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.3. Growth Factors and Receptors
            • 4.3.1.1.1.3.1. Global growth factors and receptors market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.4. Molecular Markers
            • 4.3.1.1.1.4.1. Global molecular markers market, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.5. Pathological Biomarkers
            • 4.3.1.1.1.5.1. Global pathological biomarkers market, 2018 - 2030 (USD Million)
      • 4.3.1.2. Blood Tests
        • 4.3.1.2.1. Global blood tests market, 2018 - 2030 (USD Million)
    • 4.3.2. Imaging
      • 4.3.2.1. Global Imaging Market, 2018 - 2030 (USD Million)
    • 4.3.3. Endoscopy
      • 4.3.3.1. Global Endoscopy Market, 2018 - 2030 (USD Million)
    • 4.3.4. Biopsy
      • 4.3.4.1. Global Biopsy Market, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Liver Cancer Diagnostics Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Hospitals & Diagnostic Laboratories
    • 5.5.1. Global Hospitals & Diagnostic Laboratories market, 2018 - 2030 (USD Million)
  • 5.6. Academic & Research Institutes
    • 5.6.1. Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 5.7. Pharmaceutical & CRO Laboratories
    • 5.7.1. Global Pharmaceutical & CRO Laboratories market, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. North America: SWOT Analysis
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/Reimbursement
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/Reimbursement
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/Reimbursement
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe: SWOT Analysis
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/Reimbursement
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/Reimbursement
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/Reimbursement
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/Reimbursement
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/Reimbursement
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/Reimbursement
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/Reimbursement
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/Reimbursement
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific: SWOT Analysis
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/Reimbursement
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/Reimbursement
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/Reimbursement
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/Reimbursement
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/Reimbursement
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/Reimbursement
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America: SWOT Analysis
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/Reimbursement
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/Reimbursement
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA: SWOT Analysis
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/Reimbursement
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/Reimbursement
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/Reimbursement
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Abbott Laboratories
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Services benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Thermo Fisher Scientific, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Services benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. F. Hoffmann-La Roche Ltd.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Services benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Qiagen N.V.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Services benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Siemens Healthineers
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Services benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Becton, Dickinson & Company
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Services benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Illumina, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Services benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Epigenomics AG
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Services benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Koninklijke Philips N.V.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Services benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Fujifilm Medical Systems U.S.A., Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Services benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Liver cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 North America Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 5 U.S Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 6 U.S Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 7 Canada Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 Canada Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 9 Mexico Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 10 Mexico Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 11 Europe Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 12 Europe Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 13 UK Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 14 UK Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 15 Germany Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 16 Germany Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 17 France Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 18 France Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 19 Italy Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 20 Italy Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 21 Spain Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 22 Spain Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 23 Denmark Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 24 Denmark Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 25 Sweden Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 26 Sweden Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 27 Norway Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 28 Norway Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 31 Japan Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 Japan Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 33 China Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 34 China Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 35 India Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 India Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 37 Australia Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Australia Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 39 South Korea Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 40 South Korea Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 41 Thailand Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Thailand Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 43 Latin America Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 44 Latin America Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 45 Brazil Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 46 Brazil Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 47 Argentina Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 48 Argentina Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 49 MEA Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 50 MEA Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 51 South Africa Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 52 South Africa Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 55 UAE Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 56 UAE Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Liver cancer diagnostics market: market outlook
  • Fig. 14 Liver cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Liver cancer diagnostics market driver impact
  • Fig. 20 Liver cancer diagnostics market restraint impact
  • Fig. 21 Liver cancer diagnostics market strategic initiatives analysis
  • Fig. 22 Liver cancer diagnostics market: Test type movement analysis
  • Fig. 23 Liver cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 24 Laboratory Tests Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 25 Imaging Liver Cancer Diagnostics estimates and forecast, 2018 - 2030
  • Fig. 26 Endoscopy Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 27 Biopsy Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 28 Liver cancer diagnostics market: End-use movement analysis
  • Fig. 29 Liver cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 30 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 31 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
  • Fig. 32 Pharmaceutical & CRO Laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global Liver cancer diagnostics market: Regional movement analysis
  • Fig. 34 Global Liver cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 35 Global Liver cancer diagnostics market share and leading players
  • Fig. 36 North America market share and leading players
  • Fig. 37 Europe market share and leading players
  • Fig. 38 Asia Pacific market share and leading players
  • Fig. 39 Latin America market share and leading players
  • Fig. 40 Middle East & Africa market share and leading players
  • Fig. 41 North America: SWOT
  • Fig. 42 Europe SWOT
  • Fig. 43 Asia Pacific SWOT
  • Fig. 44 Latin America SWOT
  • Fig. 45 MEA SWOT
  • Fig. 46 North America, by country
  • Fig. 47 North America
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S.
  • Fig. 50 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 51 Canada
  • Fig. 52 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 53 Mexico
  • Fig. 54 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 55 Europe
  • Fig. 56 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 57 UK
  • Fig. 58 UK market estimates and forecasts, 2018 - 2030
  • Fig. 59 Germany
  • Fig. 60 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 61 France
  • Fig. 62 France market estimates and forecasts, 2018 - 2030
  • Fig. 63 Italy
  • Fig. 64 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 65 Spain
  • Fig. 66 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 67 Denmark
  • Fig. 68 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 69 Sweden
  • Fig. 70 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 71 Norway
  • Fig. 72 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 73 Asia Pacific
  • Fig. 74 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 75 China
  • Fig. 76 China market estimates and forecasts, 2018 - 2030
  • Fig. 77 Japan
  • Fig. 78 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 79 India
  • Fig. 80 India market estimates and forecasts, 2018 - 2030
  • Fig. 81 Thailand
  • Fig. 82 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 83 South Korea
  • Fig. 84 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 85 Australia
  • Fig. 86 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 87 Latin America
  • Fig. 88 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 89 Brazil
  • Fig. 90 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 91 Argentina
  • Fig. 92 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 93 Middle East and Africa
  • Fig. 94 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 95 South Africa
  • Fig. 96 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 97 Saudi Arabia
  • Fig. 98 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 99 UAE
  • Fig. 100 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 101 Kuwait
  • Fig. 102 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 103 Market share of key market players- Liver cancer diagnostics market